List of Excipients in Branded Drug FENTANYL BUCCAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mayne Pharma	FENTANYL BUCCAL	fentanyl citrate	51862-634	ANHYDROUS CITRIC ACID
Mayne Pharma	FENTANYL BUCCAL	fentanyl citrate	51862-634	MAGNESIUM STEARATE
Mayne Pharma	FENTANYL BUCCAL	fentanyl citrate	51862-634	MANNITOL
Mayne Pharma	FENTANYL BUCCAL	fentanyl citrate	51862-634	SODIUM BICARBONATE

Fentanyl Buccal Excipient Strategy, Patent Landscape, and Commercial Opportunities

Last updated: September 5, 2026

Fentanyl buccal products compete on rapid transmucosal absorption, dose uniformity, adhesion, taste control, misuse resistance, and manufacturing reliability. The principal commercial opportunity is not a basic fentanyl tablet. It is a differentiated buccal platform that improves pharmacokinetics, tolerability, abuse deterrence, or supply economics while avoiding opioid-specific regulatory and liability risks.

What is the market for fentanyl buccal products?

Fentanyl buccal products deliver fentanyl citrate through the oral mucosa for breakthrough cancer pain in opioid-tolerant patients. The main U.S. reference products have been Actiq, an oral transmucosal lozenge, and Fentora, a buccal tablet. Generic fentanyl citrate buccal products have also entered the U.S. market.

Product	Dosage form	Sponsor or market originator	Route	Main commercial issue
Actiq	Oral transmucosal lozenge on an applicator	Cephalon, later Teva	Buccal and sublingual mucosa	Complex use, pediatric exposure risk, opioid abuse risk
Fentora	Buccal tablet	Cephalon, later Teva	Buccal mucosa	Formulation and delivery-platform competition
Generic fentanyl buccal tablets	Buccal tablet	Multiple generic companies	Buccal mucosa	Price competition and restricted market
Fentanyl sublingual or buccal films	Film or layered dosage form	Product-specific	Oral mucosa	Potential differentiation through speed, discretion, and adherence

Fentanyl buccal products are subject to the FDA’s opioid safety framework, including controlled-substance requirements and the Transmucosal Immediate Release Fentanyl Risk Evaluation and Mitigation Strategy, or TIRF REMS. They are not interchangeable with one another on a microgram-for-microgram basis because absorption and exposure vary by product and formulation. The FDA labeling for Fentora specifically restricts use to opioid-tolerant adults with breakthrough cancer pain [1].

What excipients are used in fentanyl buccal formulations?

The excipient strategy normally combines a water-soluble matrix, a mucoadhesive component, taste modifiers, pH-control agents, lubricants, and compression aids. The optimal system depends on whether the commercial objective is rapid release, prolonged mucosal residence, or lower manufacturing cost.

Core excipient functions

Formulation objective	Useful excipient classes	Commercial purpose
Rapid wetting	Mannitol, lactose, low-substituted hydroxypropyl cellulose, porous carriers	Shortens tablet disintegration time
Mucoadhesion	Carbomers, polycarbophil, hydroxypropyl cellulose, sodium carboxymethylcellulose, alginates	Keeps the dose at the buccal site
Controlled dissolution	Hydroxypropyl methylcellulose, povidone, polyethylene oxide, acrylic polymers	Controls residence time and exposure
Taste masking	Ion-exchange resins, polymer coatings, sweeteners, flavors	Reduces bitterness and improves acceptability
pH modification	Citrate, phosphate, carbonate, bicarbonate systems	Can affect fentanyl ionization and mucosal permeation
Compression	Microcrystalline cellulose, mannitol, lactose, coprocessed excipients	Supports tablet hardness and content uniformity
Lubrication	Magnesium stearate, sodium stearyl fumarate, stearic acid	Enables high-speed tableting
Moisture control	Silica, desiccant packaging, low-moisture excipient grades	Protects stability and dose performance

Fentanyl citrate is highly potent, so excipient selection must support content uniformity at very low drug loads. Segregation, adhesion to manufacturing equipment, electrostatic charging, and blend nonuniformity can create both regulatory and safety risks. A formulation that performs well at laboratory scale may fail during commercial compression because the active pharmaceutical ingredient is present at a very small fraction of the total tablet mass.

How should an excipient platform be designed for commercial differentiation?

The strongest commercial strategy is a platform that links excipient selection to measurable clinical or operational advantages. A simple change in filler or lubricant is unlikely to produce durable market protection unless it generates a meaningful product-performance difference.

Fast-release buccal tablet

A fast-release formulation uses highly water-soluble fillers, porous particles, efficient wetting, and limited polymer loading. The target profile is:

• Rapid saliva penetration
• Short disintegration time
• High early drug release
• Low residual tablet mass
• Limited swallowing of the dose
• Consistent exposure across saliva volumes and mucosal conditions

This approach may support a 505(b)(2) development strategy if the product has a materially different delivery profile from an existing reference product. A faster formulation could compete on onset, but the sponsor would need to establish that the pharmacokinetic difference is clinically meaningful and does not create a higher risk of respiratory depression.

Mucoadhesive tablet

A mucoadhesive formulation increases residence time through polymer swelling and adhesive interaction with the buccal mucosa. Carbomers, polycarbophil, cellulose derivatives, and polyethylene oxide are common candidates.

The commercial advantages include reduced dose loss from swallowing, improved reproducibility, and the potential for lower nominal dose. The disadvantages include delayed release, local irritation, variable adhesion in patients with dry mouth, and increased sensitivity to polymer grade and compression force.

A patentable product may result from a defined polymer ratio, multilayer tablet, adhesive face, impermeable backing layer, or controlled hydration sequence. The claim should focus on measurable performance, such as adhesion time, release rate, mucosal flux, or pharmacokinetic exposure, rather than a generic list of excipients.

Bilayer or unidirectional-release tablet

A bilayer tablet can place fentanyl in a drug-containing mucoadhesive layer and use a backing layer to reduce drug loss into the oral cavity. This design may improve buccal-to-systemic delivery and reduce swallowed drug.

Potential claim elements include:

• Drug-containing adhesive layer
• Non-permeable or low-permeability backing layer
• Defined polymer grades
• Layer weight ratio
• Surface area and geometry
• Adhesion time
• In vitro release and ex vivo permeation profile

The manufacturing burden is higher than for a conventional single-layer tablet. Layer weight variation, delamination, and tablet orientation must be controlled.

What formulation patents can protect fentanyl buccal products?

Formulation patents can protect the delivery system even when basic fentanyl composition patents have expired. The most valuable claim categories are:

1. Composition claims covering fentanyl, a mucoadhesive polymer, a pH modifier, and a specific filler system.
2. Dosage-form claims covering multilayer, bilayer, porous, rapidly disintegrating, or unidirectional-release tablets.
3. Performance claims tied to dissolution, adhesion, permeability, or pharmacokinetic parameters.
4. Manufacturing claims covering low-dose blending, granulation, coating, compression, or content-uniformity controls.
5. Packaging claims addressing moisture protection, child resistance, tamper evidence, or unit-dose handling.
6. Abuse-deterrent claims covering physical, chemical, or extraction-resistant designs.

The original Fentora platform was associated with OraVescent technology, which used formulation components intended to promote rapid drug release and transmucosal absorption. Published patent families associated with fentanyl buccal delivery include patents assigned to or originating from Cephalon and related entities. Patent scope, terminal disclaimers, maintenance status, and Orange Book listing status must be assessed family by family because individual claims may have different expiration dates and enforceability profiles [2][3].

When did fentanyl buccal products lose exclusivity?

Fentanyl buccal exclusivity has eroded through a combination of patent expiry, generic approvals, product discontinuations, and limited market size. The relevant dates differ by product and jurisdiction.

Exclusivity factor	Effect on market
New chemical entity exclusivity	No longer relevant to mature fentanyl products
Original formulation patents	Protecting periods have largely expired or are approaching the end of their terms, depending on family
Pediatric exclusivity	May have extended selected FDA-listed protections by six months
Orphan-related protections	Product-specific and indication-specific; not a general barrier to all fentanyl products
REMS requirements	Restrict distribution and prescribing but do not create market exclusivity
Orange Book listing	Can support an ANDA litigation pathway if an unexpired listed patent remains
Generic approval	Creates direct price pressure on conventional dosage forms

A precise expiration analysis requires review of the current FDA Orange Book entries, patent term adjustment, patent term extension, pediatric exclusivity, and any applicable terminal disclaimer. A product’s commercial exclusivity can end before the last technically related patent expires if the remaining claims do not cover the approved product or if they are not listed for ANDA purposes [4].

What is the Orange Book status of fentanyl buccal products?

The Orange Book is the controlling U.S. source for approved drug products, therapeutic equivalence ratings, and patents submitted for listed products. Fentanyl buccal tablets and related transmucosal products should be evaluated separately because Actiq and Fentora are different dosage forms with different labeling and product characteristics.

For a generic entrant, the relevant questions are:

• Is the reference product listed as currently marketed?
• Are product-specific patents still listed?
• Does the proposed product require a Paragraph IV certification?
• Is there an active 30-month litigation stay?
• Does the generic applicant seek a full label or a skinny label?
• Does the FDA assign therapeutic equivalence to the proposed dosage form?

The existence of a fentanyl buccal patent does not automatically block an ANDA. The patent must be listed for the reference product, relevant to the proposed product, and capable of supporting an infringement action under the Hatch-Waxman framework.

Which companies are challenging or competing with fentanyl buccal products?

Competition has come from generic manufacturers, alternative transmucosal products, and non-fentanyl therapies for breakthrough pain. Generic companies typically target the active ingredient and conventional dosage form rather than attempting to reproduce every proprietary delivery feature.

Competitive categories include:

• Generic fentanyl buccal tablets
• Generic oral transmucosal fentanyl products
• Fentanyl sublingual tablets
• Fentanyl sublingual sprays
• Fentanyl nasal sprays
• Non-fentanyl opioids
• Non-opioid and disease-directed pain therapies

The nasal route can offer operational advantages, including easier administration and reduced dependence on buccal placement. A buccal product can compete through discreet administration, lower device complexity, reduced nasal irritation, and a simpler unit-dose presentation.

What patent litigation affects fentanyl buccal products?

Fentanyl delivery technologies have historically generated patent disputes involving formulation architecture, absorption enhancement, rapid dissolution, and generic substitution. Hatch-Waxman litigation may arise when an ANDA applicant files a Paragraph IV certification against an Orange Book-listed patent.

Key litigation risks include:

• Infringement of composition claims
• Infringement of method-of-use claims for breakthrough cancer pain
• Disputes over whether a generic product practices a delivery-platform claim
• Induced infringement allegations based on labeling
• Patent-listing disputes
• Invalidity challenges based on obviousness, lack of written description, or enablement
• State-law and product-liability claims tied to misuse or accidental exposure

Settlement agreements can delay generic entry through a negotiated launch date, license, authorized-generic arrangement, or manufacturing relationship. Any settlement involving a controlled opioid product is also subject to regulatory and antitrust scrutiny. The Federal Trade Commission reviews many pharmaceutical patent settlements, while the FDA controls approval and labeling.

How strong is the patent estate for a new fentanyl buccal product?

A new product has the strongest patent position when it combines several independent technical layers:

IP layer	Relative value
New delivery architecture	High, if it produces a reproducible clinical advantage
Defined excipient ratio	Moderate to high when linked to performance
Manufacturing process	Moderate, especially for low-dose uniformity
Packaging and abuse deterrence	Moderate, with practical commercial value
Broad method-of-use claim	Limited if the indication and patient population are already known
Routine filler substitution	Low
Unclaimed taste improvement	Low unless supported by robust data

The most defensible portfolio generally includes composition, dosage-form, process, packaging, and use claims. Patent applications should be filed before public disclosure of dissolution, permeation, pharmacokinetic, or human-factor data.

What commercial opportunities exist for fentanyl buccal excipients?

The highest-value opportunities are:

Abuse-deterrent delivery

A formulation that resists crushing, chewing, solvent extraction, or dose dumping may support a differentiated product and premium pricing. Abuse deterrence does not eliminate overdose risk and must be supported by comparative laboratory and, where required, clinical evidence.

Pediatric-resistant and caregiver-controlled packaging

Packaging can reduce accidental exposure and support compliance with controlled-substance distribution requirements. Unit-dose, lockable, and tamper-evident designs may create licensing opportunities even when the tablet itself is not novel.

Manufacturing platforms for ultra-low-dose APIs

Excipient systems that improve blend uniformity, reduce fentanyl adhesion, and support continuous or high-containment processing can have value across potent compounds. This is a broader contract development and manufacturing opportunity than fentanyl alone.

Global product adaptation

Buccal products may require different excipient, labeling, packaging, and controlled-substance strategies in the United States, European Union, Canada, and emerging markets. Countries differ in opioid access, reimbursement, patent linkage, and regulatory expectations. A formulation with a lower manufacturing cost and stable room-temperature profile may be more commercially attractive outside the U.S. than a highly complex abuse-deterrent platform.

Licensing

Licensing targets include:

• Mucoadhesive polymer platforms
• Rapid-dissolution technologies
• Unidirectional-release tablets
• Taste-masking systems
• Abuse-deterrent excipient technologies
• Low-dose continuous manufacturing
• Child-resistant opioid packaging

The strongest licensing package combines issued or pending claims with comparative dissolution, mucosal permeation, pharmacokinetic, stability, and human-factors data.

How does fentanyl buccal compare with other transmucosal fentanyl products?

Attribute	Buccal tablet	Oral transmucosal lozenge	Sublingual product	Nasal product
Administration complexity	Moderate	High	Low to moderate	Low
Dose placement	Buccal mucosa	Oral cavity	Under tongue	Nasal cavity
Excipient importance	High	High	High	Moderate
Device dependence	Low	Applicator required	Usually low	Spray device
Potential differentiation	Adhesion, speed, dose uniformity	Lozenge design and dissolution	Rapid disintegration	Device and spray performance
Generic substitution risk	High for mature tablets	Product-specific	Increasing	Product-specific
Main commercial barrier	Opioid controls and limited indication	Safety and handling	Exposure variability	Device complexity

Key Takeaways

• Fentanyl buccal is a mature, highly regulated market with substantial generic and safety pressure.
• Excipient innovation has commercial value when it improves absorption, adhesion, taste, dose uniformity, abuse resistance, or manufacturing economics.
• Routine filler substitutions are unlikely to create strong patent protection.
• Bilayer, unidirectional, mucoadhesive, and abuse-deterrent systems offer the clearest formulation-led differentiation.
• Orange Book status, Paragraph IV certifications, patent term adjustments, and settlement agreements must be analyzed at the individual product and patent-family level.
• The strongest new-product opportunity is a controlled, clinically differentiated delivery platform supported by composition, process, packaging, and performance-based claims.
• Manufacturing IP for ultra-low-dose, high-potency oral products may create broader licensing value than a fentanyl-only formulation.

FAQs

Can a new excipient combination support a 505(b)(2) fentanyl buccal product?

Yes, if the product differs materially from the reference product and the sponsor can support the proposed route, formulation, pharmacokinetics, safety, and labeling. The regulatory pathway depends on the extent of reliance on the reference product and the clinical significance of the change.

Are mucoadhesive polymers automatically patentable in fentanyl buccal tablets?

No. A polymer alone is usually insufficient. Patent strength improves when the polymer is defined by grade, concentration, ratio, function, and demonstrated performance.

Can an abuse-deterrent fentanyl buccal product command premium pricing?

Potentially, but pricing depends on payer coverage, clinical evidence, regulatory labeling, procurement controls, and whether the abuse-deterrent attribute reduces diversion or improves handling. The FDA does not treat every abuse-deterrent formulation as equivalent to a product with abuse-deterrent labeling.

Do fentanyl buccal patents block all generic entrants?

No. Only relevant, enforceable, and properly listed patents can support a Hatch-Waxman infringement action. A generic applicant may challenge listed patents or omit a protected method of use through a skinny-label strategy.

Is fentanyl buccal formulation technology suitable for other potent drugs?

Yes. Low-dose content uniformity, mucoadhesion, taste masking, moisture protection, and containment processes can transfer to other potent oral or transmucosal compounds, subject to product-specific absorption and safety testing.

References

1. U.S. Food and Drug Administration. (2023). Fentora (fentanyl buccal tablet) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension resources. USPTO.

4. U.S. Food and Drug Administration. (2024). Transmucosal immediate-release fentanyl products risk evaluation and mitigation strategy. FDA.

5. U.S. Food and Drug Administration. (2012). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. FDA.

6. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.